UA93989C2 - Способ прогнозирования otbeta ha лечение - Google Patents

Способ прогнозирования otbeta ha лечение

Info

Publication number
UA93989C2
UA93989C2 UAA200803055A UAA200803055A UA93989C2 UA 93989 C2 UA93989 C2 UA 93989C2 UA A200803055 A UAA200803055 A UA A200803055A UA A200803055 A UAA200803055 A UA A200803055A UA 93989 C2 UA93989 C2 UA 93989C2
Authority
UA
Ukraine
Prior art keywords
growth factor
response
treatment
patient
transforming
Prior art date
Application number
UAA200803055A
Other languages
English (en)
Ukrainian (uk)
Inventor
Йоахим Мьокс
Андреас Штраусс
Герхард ЦУГМАЙЕР
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93989(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA93989C2 publication Critical patent/UA93989C2/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)

Abstract

Изобретение относится к способу прогнозирования ответа у пациента на лечение ингибитором димеризации HER, который состоит в том, что осуществляют оценку маркерного гена или комбинации маркерных генов, выбранных из группы, которая включает маркерные гены эпидермального фактора роста, трансформирующего фактора роста альфа и HER2, или комбинации маркерных генов, которая включает маркерный ген амфирегулина и маркерный ген, выбранный из группы, которая включает маркерные гены эпидермального фактора роста, трансформирующего фактора роста альфа и HER2, в биологическом образце, взятом из организма пациента, и прогнозируют ответ на лечение пациента ингибитором димеризации HER путем оценки результатов, полученных на первой стадии.
UAA200803055A 2005-08-12 2006-05-24 Способ прогнозирования otbeta ha лечение UA93989C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05017663 2005-08-12

Publications (1)

Publication Number Publication Date
UA93989C2 true UA93989C2 (ru) 2011-03-25

Family

ID=35511140

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200803055A UA93989C2 (ru) 2005-08-12 2006-05-24 Способ прогнозирования otbeta ha лечение

Country Status (32)

Country Link
US (2) US7700299B2 (ru)
EP (2) EP1915460B1 (ru)
JP (1) JP2009504142A (ru)
KR (2) KR20080034922A (ru)
CN (2) CN101405405A (ru)
AR (1) AR057323A1 (ru)
AT (2) ATE493514T1 (ru)
AU (2) AU2006281746B2 (ru)
BR (1) BRPI0615001A2 (ru)
CA (1) CA2616913A1 (ru)
CL (1) CL2010000720A1 (ru)
CR (1) CR9686A (ru)
CY (1) CY1111612T1 (ru)
DE (1) DE602006019265D1 (ru)
DK (1) DK1915460T3 (ru)
EC (1) ECSP088171A (ru)
ES (1) ES2356066T3 (ru)
HR (1) HRP20110171T1 (ru)
IL (1) IL188923A0 (ru)
MA (1) MA31549B1 (ru)
MX (1) MX2008001926A (ru)
NO (1) NO20080371L (ru)
NZ (1) NZ565270A (ru)
PL (1) PL1915460T3 (ru)
PT (1) PT1915460E (ru)
RS (1) RS51859B (ru)
RU (2) RU2408735C2 (ru)
SI (1) SI1915460T1 (ru)
TW (1) TW200741010A (ru)
UA (1) UA93989C2 (ru)
WO (1) WO2007019899A2 (ru)
ZA (1) ZA201102688B (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CN1447696A (zh) * 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
HRP20141111T1 (hr) * 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
ES2710439T3 (es) * 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) * 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
EP2899541A1 (en) * 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
JP5433189B2 (ja) * 2007-09-28 2014-03-05 承一 尾崎 Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
JP5690593B2 (ja) * 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
JP2011517555A (ja) * 2008-03-14 2011-06-16 ジェネンテック， インコーポレイテッド 薬剤耐性に関連する遺伝的変異
US8273534B2 (en) 2008-05-14 2012-09-25 Genomic Health, Inc. Predictors of patient response to treatment with EGF receptor inhibitors
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
SG177252A1 (en) 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
JP2012515353A (ja) * 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR20130105782A (ko) * 2010-04-18 2013-09-26 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 ErbB/ErbB 리간드 관련된 질병을 치료하기 위한 분자 및 이들의 사용 방법
PT2661266T (pt) * 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
AU2012318541B2 (en) * 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
US20160175401A1 (en) * 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
EP2876442A1 (en) * 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
CN106163558A (zh) 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
CN107106666A (zh) 2014-07-17 2017-08-29 布莱恩·J·赫尔尼奇 用于基于免疫的治疗的免疫原性mhcii类肽的鉴定
SI3302551T1 (sl) 2015-05-30 2024-10-30 F. Hoffmann-La Roche Ag Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
EP3325005A4 (en) * 2015-07-17 2019-03-27 Brian J. Czerniecki IDENTIFICATION OF IMMUNOGENIC MHC CLASS II PEPTIDES FOR IMMUNO-BASED THERAPY
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (zh) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Her-2的荧光免疫层析检测方法及试剂盒
CN110505880A (zh) 2016-11-04 2019-11-26 基因泰克公司 Her2阳性乳腺癌的治疗
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
AU2019272190B2 (en) 2018-05-25 2022-12-01 Bioneer Corporation Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
EP4171748A1 (en) 2020-06-29 2023-05-03 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination
AU2023324299A1 (en) * 2022-08-09 2025-02-27 Heligenics Inc. Method for evaluating clinical relevance of genetic variance

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
EP0931147A1 (en) 1996-10-18 1999-07-28 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
DK2258872T3 (da) 2002-03-13 2013-11-18 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
AU2003302821B2 (en) * 2002-12-11 2009-05-07 Cell Signaling Technology, Inc. Method for predicting the response to HER2-directed therapy
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP1613732A4 (en) 2003-04-01 2012-03-14 Monogram Biosciences Inc INTRA-CELLULAR COMPLEXES AS BIOMARKERS
AU2004291709C1 (en) 2003-05-30 2010-03-11 Astrazeneca Uk Limited Process
EP1653986A4 (en) 2003-08-01 2007-03-14 Smithkline Beecham Corp TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA
US20080113344A1 (en) 2003-10-28 2008-05-15 Ralph Wirtz Methods and Compositions for the Response Prediction of Malignant Neoplasia to Treatment
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
RU2300111C2 (ru) * 2005-06-15 2007-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ прогнозирования течения заболевания раком молочной железы

Also Published As

Publication number Publication date
MX2008001926A (es) 2008-03-24
PL1915460T3 (pl) 2011-05-31
JP2009504142A (ja) 2009-02-05
ATE493514T1 (de) 2011-01-15
TW200741010A (en) 2007-11-01
NO20080371L (no) 2008-05-09
WO2007019899A3 (en) 2007-04-05
AU2006281746A1 (en) 2007-02-22
DE602006019265D1 (de) 2011-02-10
AU2011202339A1 (en) 2011-06-09
KR20110074921A (ko) 2011-07-04
CR9686A (es) 2008-02-20
CN101705287A (zh) 2010-05-12
MA31549B1 (fr) 2010-08-02
WO2007019899A8 (en) 2010-08-05
US20100112603A1 (en) 2010-05-06
US20070037228A1 (en) 2007-02-15
RS51859B (sr) 2012-02-29
BRPI0615001A2 (pt) 2011-04-26
RU2010115252A (ru) 2011-10-27
CA2616913A1 (en) 2007-02-22
AR057323A1 (es) 2007-11-28
US7700299B2 (en) 2010-04-20
EP2196547B1 (en) 2011-12-28
EP2196547A1 (en) 2010-06-16
WO2007019899A2 (en) 2007-02-22
IL188923A0 (en) 2008-08-07
CN101405405A (zh) 2009-04-08
ES2356066T3 (es) 2011-04-04
RU2408735C2 (ru) 2011-01-10
RU2008108907A (ru) 2009-09-20
CL2010000720A1 (es) 2010-12-03
CY1111612T1 (el) 2015-10-07
EP1915460B1 (en) 2010-12-29
DK1915460T3 (da) 2011-01-31
ATE539171T1 (de) 2012-01-15
SI1915460T1 (sl) 2011-04-29
ECSP088171A (es) 2008-03-26
PT1915460E (pt) 2011-03-17
AU2006281746B2 (en) 2011-06-23
KR20080034922A (ko) 2008-04-22
EP1915460A2 (en) 2008-04-30
ZA201102688B (en) 2012-01-25
HRP20110171T1 (hr) 2011-04-30
NZ565270A (en) 2011-05-27

Similar Documents

Publication Publication Date Title
TW200741010A (en) Method for predicting the response to a treatment
DE602005025685D1 (de) Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
WO2006063042A3 (en) Selecting patients for therapy with a her inhibitor
TW200636076A (en) Method for measuring resistance or sensitivity to docetaxel
ATE523786T1 (de) In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens
WO2004035765A3 (en) Double-stranded rna structures and constructs, and methods for generating and using the same
NZ593225A (en) Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis
WO2004011624A3 (en) Double stranded rna structures and constructs, and methods for generating and using the same
BRPI0615657A2 (pt) seqüência de nucleotìdeos que codificam proteìnas inseticidas
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2007067500A3 (en) Predictors of patient response to treatment with egfr inhibitors
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
CY1115640T1 (el) Διαγνωση και αγωγη εναντι της σχιζοφρενειας
DE602004015626D1 (de) Bei brustkrebs
ATE537445T1 (de) Screening-verfahren
WO2008066769A3 (en) Genetic diagnosis of depression
WO2007016367A3 (en) Neoplastic disease-related methods, kits, systems and databases
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
MX2023006598A (es) Biomarcadores agonistas del trem2 y métodos para usarlos.
WO2007039234A8 (en) Methods and nucleic acids for the analysis of gene expression associated with tissue classification
WO2006025028A3 (en) Novel classification method of blood cells and tailor-made therapy and prevention based thereupon
EP1987165A4 (en) Gene with influence on the human memory
DE602006012995D1 (de) Brustkrebsdiagnoseverfahren
ATE531822T1 (de) Diagnose von prostatakrebs